Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TULIP: SYD985 vs Physician's Choice in HER2+ Breast Cancer
NCT03262935Phase 3Completed
- Sponsor
- Byondis
- Start
- Dec 2017
- Primary completion
- Mar 2021
- Modality
- Recombinant Proteins and Enzymes, Antibody-Drug Conjugates (ADCs), Monoclonal Antibodies
- Countries
- 11
01
Overview
A Phase 3 trial of trastuzumab duocarmazine in breast cancer, sponsored by Byondis. Started Dec 2017; status: completed.
02
Drugs
trastuzumab duocarmazine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03262935.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03262935.